- Our Story
- In Memory
Steven L. Wagner, Ph.D.
Project Scientist, Principal Investigator, UCSD School of Medicine, Department of Neurosciences
While serving in the role of chief scientific officer at TorreyPines Therapeutics, Inc. (TPTX), Wagner led the team that discovered the first non-NSAID-like and truly “notch-sparing” gamma-secretase modulators and introduced the term “gamma-secretase modulators or GSMs” in 2005 (through the discovery of a novel series of diaryl-2-aminothiazole derivatives that are more than 5,000-fold more potent at lowering Abeta 42 levels as are the NSAID-like “substrate-targeted” gamma-secretase modulators, e.g., sulindac sulphide and tarenflurbil). Since moving back to academia, into the Department of Neurosciences at UCSD in June 2009, Wagner's laboratory, in addition to designing/discovering another novel and structurally distinct, yet mechanistically related 2-aminothiazole-containing GSM chemotype, also has procured and validated all of the necessary immunochemical tools and differential screening assays (including high-throughput screening or HTS assays) that originally were discovered and validated under his direction at either SIBIA Neurosciences or TorreyPines Therapeutics, Inc. (TPTX) and were fundamental in the previously mentioned drug discovery accomplishments. These assays and reagents since have been made widely available for use in both the industrial and academic sectors.
These published papers resulted from Cure Alzheimer’s Fund support."Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease" , Arch Neurol. , July 16, 2012,"Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity." , Human Molecular Genetics , Vol 18 , Oct 15, 2009,